Boehringer Ingelheim: Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes

Jardiance (empagliflozin) is the first SGLT2 inhibitor to demonstrate a statistically significant reduction in the primary outcome of HbA1c (a marker of average blood sugar) in participants aged

Related Keywords

Lori Laffel ,Kristiane Bello ,Eli Lilly ,Lykke Hinsch Gylvin ,Jeff Emmick ,Product Development ,Eli Lilly Company ,Joslin Diabetes Center ,Professor Of Pediatrics At Harvard Medical School ,Boehringer Ingelheim ,International Diabetes Federation ,World Diabetes ,Principal Investigator ,Young Adult Section ,Harvard Medical ,Chief Medical Officer ,Vice President ,Boehringer ,Ingelheim ,Hase ,Trial ,Remonstrated ,Ijardiance ,First ,Sglt2 ,Inhibitor ,Show ,Statistically ,Significant ,Reduction ,Flood ,Sugar ,Levels ,Children ,Adolescents ,Type ,Diabetes ,